Key Takeaways
- • Bass, Berry & Sims has launched a dedicated multidisciplinary task force focused on advanced wound care, positioning itself among the nation's first law firms to establish a specialized team addressing regulatory and enforcement pressures in this sector.
- • Wound care fraud was a major component of the 2026 National Health Care Fraud Takedown, with three wound care cases accounting for nearly half of the $6.5 billion in alleged fraud charges announced by the U.S. Department of Justice last month.
- • The Skin Substitutes, Wound Care and Cellular & Tissue-Based Products Task Force advises providers, manufacturers, investors, and healthcare companies on reimbursement, FDA regulation, False Claims Act matters, government investigations, and strategic transactions.
- • Medicare and Medicaid spending on skin substitutes surged significantly following pandemic-related flexibilities that enabled expanded wound care delivery in home settings, triggering intensified regulatory scrutiny of the sector's growth trajectory.
- • The task force brings together attorneys with cross-functional expertise in healthcare fraud and abuse, FDA regulation, litigation, corporate transactions, and Medicare reimbursement to provide coordinated client guidance across complex regulatory and enforcement issues.
Summary
Bass, Berry & Sims, a Nashville-based law firm, has launched one of the nation's first dedicated task forces specifically focused on the advanced wound care industry, reflecting mounting government scrutiny of a rapidly expanding sector. The multidisciplinary Skin Substitutes, Wound Care and Cellular & Tissue-Based Products Task Force assembles attorneys with specialized expertise across healthcare fraud and abuse, FDA regulation, litigation, corporate transactions, and Medicare reimbursement to provide coordinated advisory services to clients navigating an increasingly complex regulatory environment.
The timing of this initiative coincides with heightened enforcement activity targeting the advanced wound care industry. The U.S. Department of Justice's 2026 National Health Care Fraud Takedown, announced last month, underscored the sector's prominence in federal enforcement priorities. Three wound care cases alone accounted for nearly half of the $6.5 billion in alleged fraud charges included in that announcement, indicating that wound care represents a significant focal point for federal prosecutors and investigators.
The proliferation of fraud enforcement in wound care reflects broader market dynamics. Spending on skin substitutes for Medicare and Medicaid beneficiaries expanded dramatically in the post-pandemic period, driven by regulatory flexibilities that permitted wound care treatment in home settings rather than exclusively institutional environments. This shift in delivery models created significant growth opportunities but also expanded the surface area for compliance risk and regulatory oversight.
The task force's scope encompasses reimbursement strategy, regulatory compliance, government investigations, False Claims Act defense, and strategic transactions, positioning it as a comprehensive advisory resource for providers, manufacturers, investors, and other healthcare stakeholders operating in or entering the advanced wound care market. For institutional investors and alternative investment professionals evaluating opportunities in this sector, the availability of specialized legal counsel reflects both the complexity and the risk profile associated with advanced wound care investments in the current enforcement climate.
The timing of this initiative coincides with heightened enforcement activity targeting the advanced wound care industry. The U.S. Department of Justice's 2026 National Health Care Fraud Takedown, announced last month, underscored the sector's prominence in federal enforcement priorities. Three wound care cases alone accounted for nearly half of the $6.5 billion in alleged fraud charges included in that announcement, indicating that wound care represents a significant focal point for federal prosecutors and investigators.
The proliferation of fraud enforcement in wound care reflects broader market dynamics. Spending on skin substitutes for Medicare and Medicaid beneficiaries expanded dramatically in the post-pandemic period, driven by regulatory flexibilities that permitted wound care treatment in home settings rather than exclusively institutional environments. This shift in delivery models created significant growth opportunities but also expanded the surface area for compliance risk and regulatory oversight.
The task force's scope encompasses reimbursement strategy, regulatory compliance, government investigations, False Claims Act defense, and strategic transactions, positioning it as a comprehensive advisory resource for providers, manufacturers, investors, and other healthcare stakeholders operating in or entering the advanced wound care market. For institutional investors and alternative investment professionals evaluating opportunities in this sector, the availability of specialized legal counsel reflects both the complexity and the risk profile associated with advanced wound care investments in the current enforcement climate.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.